# Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

> **NCT06793826** · — · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 713 (actual)

## Conditions studied

- Hepatitis B
- Haemophilus Influenzae Type b Immunisation

## Interventions

- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP-T combined vaccine

## Key facts

- **NCT ID:** NCT06793826
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-17
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 713 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06793826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06793826, "Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06793826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*